Detected ·
LifeMine Therapeutics
$263M—
LifeMine Therapeutics, a Watertown, MA-based biotech, raised $263M (combining a $75M Series D and an oversubscribed $188M Series E) to advance LIFE-001, a novel calcineurin activation inhibitor designed to prevent organ transplant rejection without damaging other organs. New investors include Bezos Expeditions, Gates Frontier, and RA Capital Management.
- Website
- www.lifeminetx.com
- Amount
- $263 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-09 16:01:45 UTC
- Signal ID
- de48e48a-48ce-438d-af34-fa4874723bfb
As the API returns it
{
"id": "de48e48a-48ce-438d-af34-fa4874723bfb",
"created_at": "2026-08-09T16:01:45.483706Z",
"company_name": "LifeMine Therapeutics",
"company_website_url": "www.lifeminetx.com",
"company_linkedin_url": "https://www.linkedin.com/company/lifemine-therapeutics",
"event_type": "funding",
"funding_amount": 263000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*LifeMine Therapeutics, a Watertown, MA-based biotech, raised $263M (combining a $75M Series D and an oversubscribed $188M Series E) to advance LIFE-001, a novel calcineurin activation inhibitor designed to prevent organ transplant rejection without damaging other organs. New investors include Bezos Expeditions, Gates Frontier, and RA Capital Management.*"
}